MXPA01011344A - The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders. - Google Patents

The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.

Info

Publication number
MXPA01011344A
MXPA01011344A MXPA01011344A MXPA01011344A MXPA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A MX PA01011344 A MXPA01011344 A MX PA01011344A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
protein tyrosine
prophylactic
kinase pathway
therapeutic treatment
Prior art date
Application number
MXPA01011344A
Other languages
Spanish (es)
Inventor
Juan Eugene De Jr
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Publication of MXPA01011344A publication Critical patent/MXPA01011344A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)

Abstract

The present invention is directed to a method for the prophylactic and therapeutic treatment of age-related macular degeneration as well as methods for the prophylactic and therapeutic treatment of exudative and atrophic complications of age-related macular degeneration. The methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the animal for age-related macular degeneration or an exudative or atrophic complication thereof, respectively, prophylactically or therapeutically. The present invention further provides a method for the prophylactic and therapeutic treatment of degeneration of the retina, a method for the prophylactic and therapeutic treatment of degeneration of the choroid, and a method for the prophylactic and therapeutic treatment of thickening of Bruch's membrane. These methods involve the administration of an inhibitor of the protein tyrosine kinase pathway to an animal, such as a mammal, in particular a human, in an amount sufficient to treat the macula, retina, choroid or Bruch's membrane, respectively, prophylactically or therapeutically. The inhibitor of the protein tyrosine kinase pathway is preferably genistein or an analogue or prodrug thereof or a pharmaceutically acceptable salt of any of the foregoing.
MXPA01011344A 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders. MXPA01011344A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13311299P 1999-05-07 1999-05-07
US35044099A 1999-07-09 1999-07-09
PCT/US2000/012339 WO2000067738A2 (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
MXPA01011344A true MXPA01011344A (en) 2004-06-03

Family

ID=26831056

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011344A MXPA01011344A (en) 1999-05-07 2000-05-05 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.

Country Status (6)

Country Link
EP (1) EP1178791A2 (en)
JP (1) JP4920134B2 (en)
AU (1) AU774495B2 (en)
CA (1) CA2373178C (en)
MX (1) MXPA01011344A (en)
WO (1) WO2000067738A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (en) * 2001-06-20 2002-12-27 Raouf Rekik Ophthalmological medicament for correcting vision and abrogating the need for glasses, contains an angiotension conversion enzyme inhibitor
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
WO2019146738A1 (en) * 2018-01-25 2019-08-01 国立大学法人大阪大学 Stress state detection method and stress detection device
CN114931574A (en) * 2022-06-14 2022-08-23 深圳爱尔眼科医院 Iron death inhibitor and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09316000A (en) * 1996-05-31 1997-12-09 Toagosei Co Ltd Vaccine for suppressing arterialization
JP2002513391A (en) * 1996-11-05 2002-05-08 ザ チルドレンズ メディカル センター コーポレイション Methods and compositions for inhibiting angiogenesis
WO1998040090A1 (en) * 1997-03-14 1998-09-17 The Regents Of The University Of California Methods for inhibiting bacterial cytotoxicity
JP2001518470A (en) * 1997-09-26 2001-10-16 メルク エンド カムパニー インコーポレーテッド Novel angiogenesis inhibitors
JP2002506028A (en) * 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン Use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation

Also Published As

Publication number Publication date
WO2000067738A3 (en) 2001-08-23
EP1178791A2 (en) 2002-02-13
CA2373178A1 (en) 2000-11-16
WO2000067738A2 (en) 2000-11-16
AU4988400A (en) 2000-11-21
CA2373178C (en) 2013-07-02
JP2002544159A (en) 2002-12-24
JP4920134B2 (en) 2012-04-18
AU774495B2 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
CA2321560A1 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
Gros Spasticity—clinical classification and surgical treatment
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO1998010767A3 (en) Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
CA2213833A1 (en) Vascular endothelial cell growth factor antagonists
EP2514420A3 (en) Use of rapamycin for the treatment or prevention of age-related macular degeneration
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
IL175875A0 (en) Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
NO970517L (en) Topical ophthalmic formulations containing doxepin derivatives for the treatment of ocular allergy diseases
WO2005102303A3 (en) Antiprostaglandins for the treatment of ocular pathologies
EP1074258A3 (en) Methods and compositions for treating diseases and conditions of the eye
CA2262268C (en) Method of treating impotence due to spinal cord injury
IS8096A (en) Use of carbamazepine derivatives to treat patient agitation is dementia sufferers
WO2002047673A3 (en) Methods and compositions to treat conditions associated with neovascularization
MXPA01011344A (en) The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders.
BG105875A (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
ATE161725T1 (en) USE OF PHOSPHATE DIESTERS TO TREAT RETINA DISEASES
MXPA03001160A (en) Method of treating neurodegenerative disorders of the retina and optic nerve head.
EP1037622A4 (en) Taurine derivatives usable in the treatment of ophthalmic disorders
AU6418296A (en) Aromatic acid diamides with antigastrin activity, a method for their preparation and their pharmaceutical use
WO1998024898A3 (en) Therapeutic composition comprising the kal protein and use of the kal protein
EP1482922A4 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
MXPA04001255A (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma.
DE60027878D1 (en) USE OF THE NERVE GROWTH FACTOR FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISEASES OF THE INTERIOR ENVIRONMENT

Legal Events

Date Code Title Description
FG Grant or registration